

MusclePharm Corp  
Form 8-K  
November 09, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**November 9, 2016**

**Date of report (date of earliest event reported)**

**MusclePharm Corporation**

**(Exact name of registrant as specified in its charter)**

<b>Nevada</b>	<b>000-53166</b>	<b>77-0664193</b>
<b>(State or other jurisdictions of</b>	<b>(Commission</b>	<b>(I.R.S.</b>
<b>incorporation or organization)</b>	<b>File Number)</b>	<b>Employer</b>
		<b>Identification</b>
		<b>Nos.)</b>

**4721 Ironton Street, Building A**

**Denver, Colorado 80239**

**(Address of principal executive offices) (Zip Code)**

**(303) 396-6100**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrants under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02. Results of Operations and Financial Condition.**

On November 9, 2016, MusclePharm Corporation issued a press release announcing its financial results for the quarter ended September 30, 2016. A copy of the press release is furnished hereto as Exhibit 99.1.

The information contained in this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be “filed” for any purpose, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of general incorporation language in any such filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
------------------------	--------------------

99.1	Press release issued by MusclePharm Corporation, dated November 9, 2016, announcing financial results.
------	--

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MUSCLEPHARM  
CORPORATION**

By: /s/ Ryan Drexler  
Name: Ryan  
Drexler  
Title: Interim Chief  
Executive Officer  
and Interim  
President  
Date: November 9, 2016

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release issued by MusclePharm Corporation, dated November 9, 2016, announcing financial results.

